Gilead’s Captisol-enabled Remdesivir Approved for Use in Renally Impaired Patients
Read full release and find prescribing information



3911 Sorrento Valley Road
Suite 110
San Diego, CA 92121

Jessica Beach
Assoc. Director, Captisol Customer Support
P: 877-575-5593

This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.


Vince Antle, PhD, Senior Vice President, Technical Operations

Vince Antle, PhD

Senior Vice President, Technical Operations

Dr. Antle joined Ligand in 2011 following Ligand's acquisition of CyDex Pharmaceuticals. He joined CyDex in 2005. Dr. Antle is currently responsible for quality assurance, internal drug product quality, operations, distribution and logistics for Captisol. From 1999 to 2005 Dr. Antle was Technical Operations Manager and Head of Process Development at EaglePicher Pharmaceuticals Services. Prior to 1999, Vince was the Group Leader for the Combinatorial Chemistry Department of MDS Panlabs in Bothell Washington. Dr. Antle has contributed to publications, presentation and patents and holds a Ph.D. from the University of Cincinnati in Medicinal Chemistry, and a B.A. in Chemistry from the University of Minnesota, Morris.

James Pipkin, PhD, Vice President, New Product Development

James Pipkin, PhD

Vice President, New Product Development

Dr. Pipkin joined Ligand in 2011, following Ligand's acquisition of CyDex Pharmaceuticals. He joined CyDex in 2001. Dr. Pipkin's responsibilities include leading internal or assisting clients with development of new applications, intellectual property and products utilizing CAPTISOL, whether the application involves new molecular entities (NMEs), an Orphan designated drug, or reformulations of existing drugs for life cycle management via the 505(b)(2) regulatory pathway. Prior to joining the Company, he was Executive Director for CMC Services and Director of Formulation Development at Oread Laboratories from 1995 to 2001. From 1986 through 1995, he was a Research Fellow with Merck Research Laboratories in the INTERx Research Division and West Point PR&D facilities; his area of research interest was in the design and evaluation of controlled release devices for ophthalmic and oral delivery to enhance therapeutic efficacy and lower systemic burden. He was at The Squibb Institute for Medical Research from 1980 through 1985, where he directed the preformulation activities for new chemical entities. He has contributed to numerous presentations, publications and patents and holds a M.S. and Ph.D. from The University of Kansas in Pharmaceutical Chemistry, and B.A. in Mathematics and Chemistry from Kansas University.

Lian Rajewski, PhD, Senior Investigator

Lian Rajewski, PhD

Senior Investigator

Dr. Rajewski joined Ligand in October 2020.  Her current responsibilities include designing and performing analytical and formulation studies to support internal projects, client projects, and intellectual property .  Prior to joining Ligand, Lian was a Research Professor for 11 years at the University of Kansas, Biopharmaceutics Innovation and Optimization Center where she participated in and managed many formulation, pre-formulation, analytical, and bioanalytical projects, including many development projects involving Captisol.  From 2000-2007, Dr. Rajewski held multiple roles at Aptuit its predecessor company, Quinitles, including Director of Solids Formulation Development, Senior Manager, and Senior Scientist.  Prior to that, Lian was a Senior Scientist at Oread Laboratories.  From 1995-1998 Lian worked in the Solids Formulation Development at Hoechst Marion Roussel and its predecessor company, Marion Merrel Dow.  Lian began her career at Merck Research Laboratories, INTERx Research Division.  Lian has contributed to publications and patents and holds a M.S. and Ph.D. from the University of Kansas in Pharmaceutical Chemistry, and B.S. in Pharmacy from the University of Connecticut.

Jessica Wolzen, Associate Director, Regulatory & Operations

Jessica Wolzen

Associate Director, Regulatory & Operations

Jessica Wolzen re-joined Ligand in 2018, but has been working with Vince, JD, and the Captisol team since 2006 while working at CyDex Pharmaceuticals. Her role includes regulatory responsibilities such as maintaining the multiple Captisol Drug Master Files, handling submissions to global health agencies, and providing our partners with access to our extensive safety and CMC data. Her role also includes Captisol operations, managing inventory, and coordinating with our partners to distribute Captisol around the world. And she heads Ligand’s environmental committee, which is committed to positive community engagement, employee education, and reducing our environmental impact. She obtained a B.S. in Biology from Kansas State University.

Jessica Beach, Associate Director, Captisol Customer Support

Jessica Beach

Associate Director, Captisol Customer Support

Jessica Beach re-joined Ligand in 2022 after taking a break to stay at home with her 3 children. She is very familiar with the Captisol business and the technology. Her roles include Captisol customer support. From orders to technical questions, Jessica is your main point of contact. She also manages the Captisol marketing and website activities and coordination of annual conferences. Jessica obtained her Bachelors Degree in Community Health from Kansas University.

Joanna Krise, B.Sc.Hons, Scientist

Joanna Krise, B.Sc.Hons


Jo Krise joined Ligand in 2022 in the role of scientist.  Jo’s responsibilities include analytical method development and formulation development support.  She has 26 years of broad-based laboratory experience in the pharmaceutical, molecular biology and medicinal chemistry fields, acquired both in academic and industrial settings. She obtained her Bachelor of Science and Honours degrees in Biochemistry from Monash University, Victoria, Australia.